Show simple item record

dc.contributor.authorGibb, Adam
dc.contributor.authorJones, Craig
dc.contributor.authorBloor, Adrian
dc.contributor.authorKulkarni, Samar
dc.contributor.authorIllidge, Timothy M
dc.contributor.authorLinton, Kim M
dc.contributor.authorRadford, John A
dc.date.accessioned2013-08-05T13:34:49Z
dc.date.available2013-08-05T13:34:49Z
dc.date.issued2013
dc.identifier.citationBrentuximab vedotin in refractory CD30+ lymphomas: a bridge to allogeneic transplantation in approximately one quarter of patients treated on a named patient programme at a single UK center 2012, 98 (4):611 Haematologicaen_GB
dc.identifier.issn0390-6078
dc.identifier.issn1592-8721
dc.identifier.doi10.3324/haematol.2012.069393
dc.identifier.urihttp://hdl.handle.net/10541/297412
dc.language.isoenen
dc.relation.urlhttp://www.haematologica.org/cgi/doi/10.3324/haematol.2012.069393en_GB
dc.rightsArchived with thanks to Haematologicaen_GB
dc.titleBrentuximab vedotin in refractory CD30+ lymphomas: a bridge to allogeneic transplantation in approximately one quarter of patients treated on a named patient programme at a single UK centeren
dc.typeArticleen
dc.contributor.departmentThe Christie NHS Foundation Trust, Wilmslow Road, Withington, Manchester, M20 9BX, UKen_GB
dc.identifier.journalHaematologicaen_GB


This item appears in the following Collection(s)

Show simple item record